All In Biotech

Drug Trial Radar · NCT04890613

Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation

Phase Ib Expansion Study of CX-5461 in Patients With Solid Tumours and BRCA2 and/or PALB2 Mutation

Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

52

Planned (sponsor's estimate)

Start

Sep 8, 2021

Primary completion

Mar 2027

Study completion Mar 2027

Sponsor

Lead sponsor
Senhwa Biosciences, Inc.Industry
Sponsor type
Industry
First posted
May 18, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, multi-center, phase 1b study designed to determine a tolerable dose of CX-5461 administered by IV infusion on Day 1 and Day 8 of a 28-day cycle in patients with selected solid tumours and associated mutations for future Phase II trials. The safety and tolerability of CX-5461, preliminary evidence of antitumor effect and the effect of CX-5461 on the Health-Related Quality of Life (HRQoL) will also be evaluated. The study will also evaluate the predictive value of mutational signatures and explore the significance of dynamic changes in ctDNA levels and plasma DNA methylome profiling in this study's exploratory cohort.

Conditions

  • Advanced Solid Tumor

Interventions

  • CX-5461Drug

    150 mg sterile lyophilized powder containing 1% sucrose

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Determination of Recommended Phase 2 Dose (RP2D)Time frame: Safety cohort review will be conducted every 4 weeks from the date of first patient's enrollment to review safety data, until all patients have been enrolled and evaluated for toxicity.

Locations

7 sites in 2 countries. Site status is shown where the registry gives one.

  • University of California, Los Angeles

    Santa Monica, California

  • H. Lee Moffitt Cancer Center and Research Institute Hospital

    Tampa, Florida

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • Ohio State University-James Cancer Hospital and Solove Research Institute

    Columbus, Ohio

  • UPMC Hillman Cancer Center

    Pittsburgh, Pennsylvania

  • Princess Margaret Cancer Centre

    Toronto, Ontario, Canada

  • Centre hospitalier de l'Université de Montréal (CHUM)

    Montreal, Quebec, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.